Biosulin R, 100 me/ml 3 ml cartridges 5 pcs

Biosulin P, short-acting insulin, is human insulin produced using recombinant DNA technology.

It interacts with specific receptor of outer cytoplasmic cell membrane and forms insulin-receptor complex, stimulating intracellular processes including synthesis of several key enzymes (hexokinase, pyruvate kinase, glycogen synthetase).

Lower blood glucose content is due to increased intracellular transport, increased absorption and assimilation by tissues, stimulation of lipogenesis and glycogenogenesis and decreased rate of glucose production by liver.

The duration of action of Biosulin P is mainly determined by the rate of absorption, which depends on several factors (such as dose, route and place of administration) and therefore the action profile of insulin is subject to significant variations both in different people and in the same person.

After p/q administration, the onset of action of Biosulin R is observed in approximately 30 min, the maximum effect is between 2 and 4 h, the duration of action is 6-8 h.

Indications

— diabetes mellitus type 1 (insulin dependent);
– diabetes mellitus type 2 (non-insulin dependent): stage of resistance to oral hypoglycemic agents, partial resistance to these drugs (during combination therapy), intercurrent diseases.
— emergency conditions in patients with diabetes mellitus, accompanied by decompensation of carbohydrate metabolism

Pharmacological effect

Biosulin R – short-acting insulin, is a human insulin obtained using recombinant DNA technology.

Interacts with a specific receptor on the outer cytoplasmic membrane of cells and forms an insulin-receptor complex that stimulates intracellular processes, incl. synthesis of a number of key enzymes (hexokinase, pyruvate kinase, glycogen synthetase).

The decrease in blood glucose levels is due to an increase in its intracellular transport, increased absorption and assimilation by tissues, stimulation of lipogenesis, glycogenogenesis, and a decrease in the rate of glucose production by the liver.

The duration of action of Biosulin R is mainly determined by the rate of absorption, which depends on several factors (for example, on the dose, route and site of administration), and therefore the action profile of insulin is subject to significant fluctuations, both in different people and in the same person.

After subcutaneous administration, the onset of action of Biosulin R is observed after approximately 30 minutes, the maximum effect is in the interval between 2 and 4 hours, the duration of action is 6-8 hours.

Special instructions

Do not use Biosulin P if, after shaking, the suspension does not become white and uniformly cloudy.

During insulin therapy, constant monitoring of blood glucose levels is necessary.

Active ingredient

Insulin soluble human genetically engineered

Composition

1 ml of injection solution contains:

active substance:

human isophane insulin 100 units;

excipients:

glycerol;

metacresol;

water for injections

Pregnancy

Data on the use of the drug during pregnancy and breastfeeding are not provided.

Contraindications

— hypoglycemia;
– hypersensitivity to insulin or other components of the drug Biosulin N.

Side Effects

Metabolism: hypoglycemic conditions (pallor of the skin, increased sweating, palpitations, tremor, hunger, agitation, paresthesia in the mouth, headache).

Severe hypoglycemia can lead to the development of hypoglycemic coma.

Allergic reactions: rarely – skin rash, Quincke’s edema; in some cases – anaphylactic shock.

Local reactions: hyperemia, swelling and itching at the injection site; with long-term use – lipodystrophy at the injection site.
Other: edema, transient refractive errors (usually at the beginning of therapy).

Interaction

There are a number of medications that affect the need for insulin.

The hypoglycemic effect of insulin is enhanced by oral hypoglycemic drugs, MAO inhibitors, non-selective beta-blockers, ACE inhibitors, sulfonamides, anabolic steroids, carbonic anhydrase inhibitors, bromocriptine, octreotide, tetracyclines, clofibrate, ketoconazole, mebendazole, pyridoxine, theophylline, cyclophosphamide, fenfluramine, lithium preparations, preparations containing ethanol.

The hypoglycemic effect of insulin is reduced by oral contraceptives, corticosteroids, thyroid hormones, thiazide diuretics, heparin, tricyclic antidepressants, sympathomimetics, danazol, clonidine, calcium channel blockers, diazoxide, morphine, phenytoin, nicotine.

Under the influence of reserpine and salicylates, it is possible to both weaken and enhance the effect of the drug.

Overdose

Symptoms: hypoglycemia may develop.

Treatment: the patient can eliminate mild hypoglycemia himself by ingesting sugar or carbohydrate-rich foods (diabetes patients are advised to carry sugar, sweets, cookies or sweet fruit juice with them at all times).

In severe cases, in case of loss of consciousness, a 40% dextrose solution is administered intravenously; IM, SC or IV – glucagon.

After regaining consciousness, the patient is advised to take a carbohydrate-rich meal to prevent the recurrence of hypoglycemia.

Storage conditions

In a place protected from light, at a temperature of 2–8 °C (do not freeze)

Shelf life

2 years

Manufacturer

Pharmstandard-UfaVITA, Russia